Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
6(38%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_4
4
25%
Ph phase_2
2
13%
Ph phase_3
8
50%
Ph not_applicable
1
6%

Phase Distribution

0

Early Stage

2

Mid Stage

12

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
2(13.3%)
Phase 3Large-scale testing
8(53.3%)
Phase 4Post-market surveillance
4(26.7%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

16

all time

Status Distribution
Active(6)
Completed(7)
Other(3)

Detailed Status

Completed7
Recruiting6
unknown3

Development Timeline

Analytics

Development Status

Total Trials
16
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (13.3%)
Phase 38 (53.3%)
Phase 44 (26.7%)
N/A1 (6.7%)

Trials by Status

unknown319%
recruiting638%
completed744%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT07018700Phase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Recruiting
NCT07018713Phase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Recruiting
NCT03977493Phase 3

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Recruiting
NCT06995287Phase 3

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea

Recruiting
NCT04908423Phase 4

Xeomin® and Gait Related Mobility After Stroke

Recruiting
NCT06205797Phase 3

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Recruiting
NCT05980559Phase 3

Evaluation of BTX Injections in Treatment of Bruxism

Unknown
NCT05298449Phase 2

Phase 2 of HU-045 in Glabellar Lines

Completed
NCT05623410Phase 3

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Unknown
NCT01486264Phase 4

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Completed
NCT04102670Not Applicable

Combination Therapy for Rejuvenation of the Lower Face and Neck

Unknown
NCT01728337Phase 4

Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum

Completed
NCT02188277Phase 2

Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy

Completed
NCT01678001Phase 4

Treatment of Plantar Fasciitis With Xeomin

Completed
NCT01287247

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Completed
NCT01098019Phase 3

Treatment of Notalgia Paresthetica With Xeomin

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16